Riedl, Marc A <br/><br/>
Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study.  [electronic resource] 

 -  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology  Apr 2013 
 - 295-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1534-4436 
<br/><br/><label>Standard No.: </label>10.1016/j.anai.2013.02.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Angioedemas, Hereditary--drug therapy<br/>Complement C1 Inhibitor Protein--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>North America<br/>Recombinant Proteins--administration & dosage<br/>Treatment Outcome<br/>Young Adult